BiotechTube

Furmonertinib + Furmonertinib + Furmonertinib + Furmonertinib + Furmonertinib

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Small Cell Lung Cancer (NSCLC)

Conditions

Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I

Trial Timeline

Jun 30, 2022 → Dec 31, 2026

NCT ID
NCT05364073

About Furmonertinib + Furmonertinib + Furmonertinib + Furmonertinib + Furmonertinib

Furmonertinib + Furmonertinib + Furmonertinib + Furmonertinib + Furmonertinib is a phase 1 stage product being developed by ArriVent Biopharma for Non-Small Cell Lung Cancer (NSCLC). The current trial status is active. This product is registered under clinical trial identifier NCT05364073. Target conditions include Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Non-Small Cell Lung Cancer (NSCLC) were approved

Approved (20) Terminated (2) Active (0)
✅pemetrexedEli LillyApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅Gefitinib + PlaceboAstraZenecaApproved
✅Gefitinib + gemcitabine + carboplatinAstraZenecaApproved
✅PembrolizumabMerckApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05364073Phase 1Active

Competing Products

20 competing products in Non-Small Cell Lung Cancer (NSCLC)

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
pemetrexed + erlotinibEli LillyPhase 2
35
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
LY2875358 + ErlotinibEli LillyPhase 2
35
AdjuvantInsight Molecular DiagnosticsPre-clinical
8
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
44
Enzastaurin HCLEli LillyPhase 2
35
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
25
pemetrexed + gemcitabineEli LillyPhase 2
35
ALIMTA + CarboplatinEli LillyPhase 2
35
Tomivosertib + Pembrolizumab + PemetrexedeFFECTOR TherapeuticsPhase 2
29
Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + CisplatinChugai PharmaceuticalPhase 3
47